AUGTYRO (repotrectinib)
NTRK-Positive Solid Tumors
ApprovedApproved in China (Jan 2026)
Key Facts
About Zai Lab
Zai Lab is a patient-focused, global biopharma founded in 2014 with a mission to bridge scientific innovation from the West with deep market access and development capabilities in Greater China. The company has established itself as a fully integrated organization with eight commercialized products in China and a promising pipeline of internally discovered and in-licensed assets. Its core strategy combines a hybrid business model of strategic partnerships and internal R&D to address significant unmet medical needs across its core therapeutic areas.
View full company profile